Forte Biosciences (FBRX) Other Non-Current Liabilities (2016 - 2026)
Forte Biosciences (FBRX) posted quarterly Other Non-Current Liabilities of $1.5 million for Q1 2026, up 42.33% quarter-over-quarter from $1.0 million in Q4 2025.
Powered by 
Analysis
Forte Biosciences (FBRX) Other Non-Current Liabilities (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has reported Other Non-Current Liabilities for 5 consecutive years, with $1.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Liabilities changed N/A year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $1.5 million (changed N/A YoY), while the FY2025 annual figure was $1.0 million, changed N/A from the prior year.
- Other Non-Current Liabilities climbed to $1.5 million in Q1 2026 per FBRX's latest filing, from $1.0 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $1.5 million in Q1 2026 and bottomed at $1.0 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn |
| 10 | Forte Biosciences | 1.58 Bn | 1.23 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.66 Mn |
| Mar 31, 2026 | 1.48 Mn |
| Dec 31, 2025 | 1.04 Mn |
| Dec 31, 2019 | 81,000.00 |
| Sep 30, 2019 | 81,000.00 |
| Mar 31, 2017 | 67,000.00 |
| Dec 31, 2016 | 126,000.00 |